Rituximab biobetter - United BioPharma
Alternative Names: Rituxan®; UB-923Latest Information Update: 05 Nov 2023
At a glance
- Originator United BioPharma
- Class Antineoplastics; Antirheumatics; Biobetters; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Chronic lymphocytic leukaemia
- No development reported Lymphoma
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Lymphoma in Taiwan (Parenteral)
- 15 Oct 2021 Early research in Chronic lymphocytic leukaemia in Taiwan (Parenteral) (United Biopharma pipeline, October 2021)
- 15 Oct 2021 Preclinical trials in Chronic lymphocytic leukaemia in China (Parenteral) (United Biopharma pipeline, October 2021)